Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Caroline MacCallum

Advertisement

Articles by Caroline MacCallum

48 Validation of a Multi-omic Biosignature to Predict Locoregional Recurrence Risk and the Benefit of Adjuvant Radiation Therapy in Women With Early-Stage Invasive Breast Cancer Treated With Breast-Conserving Surgery and Endocrine Therapy

ByG. Bruce Mann,Karuna Mittal,Richard De Boer,Caroline MacCallum,Michael D. Alvarado,Michael Christie,Frank Vicini, MD,Chirag Shah, MD,Y. V. Zou,Mark Mentrikoski,Jess Savala,David J. Dabbs,Steven C. Shivers,Pat W. Whitworth,Troy Bremer
June 24th 2026

In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

    2

    Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

    3

    NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing

    4

    Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

    5

    EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us